Lancet:早期乳腺癌内分泌治疗——芳香化酶抑制剂 vs 他莫昔芬(Meta)

2015-10-18 Mechront 译 MedSci原创

临床上对于早期乳腺癌患者内分泌治疗的优先选择尚不明确,究竟是选芳香化酶抑制剂还是他莫昔芬。研究者就该问题进行了一项荟萃分析,涉及31,920 名绝经后、雌激素受体阳性的早期乳腺癌患者,随机进行了长达5年的芳香化酶抑制剂 vs 5年的他莫昔芬治疗;5年的芳香化酶抑制剂 vs 2-3年他莫昔芬+随后芳香化酶抑制剂治疗(总共5年时间);2-3年他莫昔芬+随后芳香化酶抑制剂治疗(总共5年时间) vs 5年

临床上对于早期乳腺癌患者内分泌治疗的优先选择尚不明确,究竟是选芳香化酶抑制剂还是他莫昔芬。研究者就该问题进行了一项荟萃分析,涉及31,920 名绝经后、雌激素受体阳性的早期乳腺癌患者,随机进行了长达5年的芳香化酶抑制剂 vs 5年的他莫昔芬治疗;5年的芳香化酶抑制剂 vs 2-3年他莫昔芬+随后芳香化酶抑制剂治疗(总共5年时间);2-3年他莫昔芬+随后芳香化酶抑制剂治疗(总共5年时间) vs 5年的他莫昔芬治疗。原始结局指标为乳腺癌复发率、乳腺癌死亡率、非复发死亡、全死因死亡情况。

5年的芳香化酶抑制剂 vs 5年的他莫昔芬

关于复发率,芳香化酶抑制剂效果更佳:0-1年 RR 0·64, 95% CI 0·52-0·78;2-4年 RR 0·80, 0·68-0·93;其后两组差异不大。关于死亡率芳香化酶抑制剂组更低:12·1% vs 14·2%; RR 0·85, 0·75-0·96; 2p=0·009。

5年的芳香化酶抑制剂 vs 2-3年他莫昔芬+随后芳香化酶抑制剂治疗(总共5年时间)

关于复发率,芳香化酶抑制剂组0-1年更低:RR 0·74, 0·62-0·89;之后两组差异不大;不过5年复发率在单纯用芳香化酶抑制剂的人群中稍低:RR
0·90, 0·81-0·99; 2p=0·045;不过单纯使用芳香化酶抑制剂对5年乳腺癌死亡率的影响并不显著:RR 0·89, 0·78-1·03; 2p=0·11。

2-3年他莫昔芬+随后芳香化酶抑制剂治疗(总共5年时间) vs 5年的他莫昔芬治疗

关于复发率,使用芳香化酶抑制剂,2-4年复发率更低RR 0·56, 0·46-0·67;但其后时间不显著;使用他莫昔芬+芳香化酶抑制剂组的10年乳腺癌死亡率比单纯使用他莫昔芬更低:8·7% vs 10·1%; 2p=0·015。

总结以上三种比较,治疗存在差异的时候,芳香化酶抑制剂可以降低复发率RR 0·70, 0·64-0·77,但之后的数据比较无显著差异。两种药物治疗时均可以减少乳腺癌死亡率RR 0·79, 0·67-0·92;其后死亡率稍微降低RR 0·89, 0·81-0·99;将两段时间合并后分析,死亡率下降情况:RR 0·86, 0·80-0·94; 2p=0·0005。全死因死亡率也在下降:RR 0·88, 0·82-0·94; 2p=0·0003。对年龄、BMI、分期分级、孕激素受体或HER2情况进行分层分析后,前后差异很小。研究者还发现,使用芳香化酶抑制剂有更少的子宫内膜癌发生率(10年)0·4% vs 1·2%; RR 0·33, 0·21-0·51;但是有更多的骨折发生率(5年)8·2% vs 5·5%; RR 1·42, 1·28-1·57;不是因乳腺癌导致的死亡率两组差异不大。

研究结果表明,对早期乳腺癌患者行内分泌治疗时,芳香化酶抑制剂比他莫昔芬可以降低约30%的复发,但是治疗后两组差异不大。并且,芳香化酶抑制剂治疗5年与他莫昔芬治疗5年相比,可以减少约15%的乳腺癌死亡率;与不进行内分泌治疗相比,则可以减少约40%的死亡率。

原始出处:

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Dowsett M, Forbes JF,et al.Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.Lancet. 2015 Oct 3;386(10001):1341-52.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1887470, encodeId=9175188e47080, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Mar 17 22:08:00 CST 2016, time=2016-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851268, encodeId=d3821851268c3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 27 02:08:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682222, encodeId=a5ec168222237, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Mon Dec 14 20:08:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895843, encodeId=1b661895843d2, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Nov 16 21:08:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828249, encodeId=ece818282495b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Apr 20 15:08:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40063, encodeId=1b4c40063d2, content=这样子啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210115/76593437d46348539f22a2d4a7a1bbb2/8f1af15837d840569d1f9ef84030d8f5.jpg, createdBy=6a601655410, createdName=一路花开, createdTime=Wed Oct 21 11:53:00 CST 2015, time=2015-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360807, encodeId=c834136080e6e, content=<a href='/topic/show?id=14dd869559e' target=_blank style='color:#2F92EE;'>#芳香化酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86955, encryptionId=14dd869559e, topicName=芳香化酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Tue Oct 20 13:08:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362713, encodeId=cd021362e13cf, content=<a href='/topic/show?id=2ebc2535658' target=_blank style='color:#2F92EE;'>#他莫昔芬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25356, encryptionId=2ebc2535658, topicName=他莫昔芬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Tue Oct 20 13:08:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39759, encodeId=8d2b39e5908, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Mon Oct 19 19:23:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39494, encodeId=c199394940f, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:03:00 CST 2015, time=2015-10-19, status=1, ipAttribution=)]
    2016-03-17 guojianrong
  2. [GetPortalCommentsPageByObjectIdResponse(id=1887470, encodeId=9175188e47080, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Mar 17 22:08:00 CST 2016, time=2016-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851268, encodeId=d3821851268c3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 27 02:08:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682222, encodeId=a5ec168222237, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Mon Dec 14 20:08:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895843, encodeId=1b661895843d2, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Nov 16 21:08:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828249, encodeId=ece818282495b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Apr 20 15:08:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40063, encodeId=1b4c40063d2, content=这样子啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210115/76593437d46348539f22a2d4a7a1bbb2/8f1af15837d840569d1f9ef84030d8f5.jpg, createdBy=6a601655410, createdName=一路花开, createdTime=Wed Oct 21 11:53:00 CST 2015, time=2015-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360807, encodeId=c834136080e6e, content=<a href='/topic/show?id=14dd869559e' target=_blank style='color:#2F92EE;'>#芳香化酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86955, encryptionId=14dd869559e, topicName=芳香化酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Tue Oct 20 13:08:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362713, encodeId=cd021362e13cf, content=<a href='/topic/show?id=2ebc2535658' target=_blank style='color:#2F92EE;'>#他莫昔芬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25356, encryptionId=2ebc2535658, topicName=他莫昔芬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Tue Oct 20 13:08:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39759, encodeId=8d2b39e5908, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Mon Oct 19 19:23:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39494, encodeId=c199394940f, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:03:00 CST 2015, time=2015-10-19, status=1, ipAttribution=)]
    2016-06-27 jklm09
  3. [GetPortalCommentsPageByObjectIdResponse(id=1887470, encodeId=9175188e47080, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Mar 17 22:08:00 CST 2016, time=2016-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851268, encodeId=d3821851268c3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 27 02:08:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682222, encodeId=a5ec168222237, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Mon Dec 14 20:08:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895843, encodeId=1b661895843d2, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Nov 16 21:08:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828249, encodeId=ece818282495b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Apr 20 15:08:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40063, encodeId=1b4c40063d2, content=这样子啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210115/76593437d46348539f22a2d4a7a1bbb2/8f1af15837d840569d1f9ef84030d8f5.jpg, createdBy=6a601655410, createdName=一路花开, createdTime=Wed Oct 21 11:53:00 CST 2015, time=2015-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360807, encodeId=c834136080e6e, content=<a href='/topic/show?id=14dd869559e' target=_blank style='color:#2F92EE;'>#芳香化酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86955, encryptionId=14dd869559e, topicName=芳香化酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Tue Oct 20 13:08:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362713, encodeId=cd021362e13cf, content=<a href='/topic/show?id=2ebc2535658' target=_blank style='color:#2F92EE;'>#他莫昔芬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25356, encryptionId=2ebc2535658, topicName=他莫昔芬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Tue Oct 20 13:08:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39759, encodeId=8d2b39e5908, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Mon Oct 19 19:23:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39494, encodeId=c199394940f, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:03:00 CST 2015, time=2015-10-19, status=1, ipAttribution=)]
    2015-12-14 gwc392
  4. [GetPortalCommentsPageByObjectIdResponse(id=1887470, encodeId=9175188e47080, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Mar 17 22:08:00 CST 2016, time=2016-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851268, encodeId=d3821851268c3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 27 02:08:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682222, encodeId=a5ec168222237, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Mon Dec 14 20:08:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895843, encodeId=1b661895843d2, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Nov 16 21:08:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828249, encodeId=ece818282495b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Apr 20 15:08:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40063, encodeId=1b4c40063d2, content=这样子啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210115/76593437d46348539f22a2d4a7a1bbb2/8f1af15837d840569d1f9ef84030d8f5.jpg, createdBy=6a601655410, createdName=一路花开, createdTime=Wed Oct 21 11:53:00 CST 2015, time=2015-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360807, encodeId=c834136080e6e, content=<a href='/topic/show?id=14dd869559e' target=_blank style='color:#2F92EE;'>#芳香化酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86955, encryptionId=14dd869559e, topicName=芳香化酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Tue Oct 20 13:08:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362713, encodeId=cd021362e13cf, content=<a href='/topic/show?id=2ebc2535658' target=_blank style='color:#2F92EE;'>#他莫昔芬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25356, encryptionId=2ebc2535658, topicName=他莫昔芬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Tue Oct 20 13:08:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39759, encodeId=8d2b39e5908, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Mon Oct 19 19:23:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39494, encodeId=c199394940f, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:03:00 CST 2015, time=2015-10-19, status=1, ipAttribution=)]
    2015-11-16 一闲
  5. [GetPortalCommentsPageByObjectIdResponse(id=1887470, encodeId=9175188e47080, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Mar 17 22:08:00 CST 2016, time=2016-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851268, encodeId=d3821851268c3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 27 02:08:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682222, encodeId=a5ec168222237, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Mon Dec 14 20:08:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895843, encodeId=1b661895843d2, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Nov 16 21:08:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828249, encodeId=ece818282495b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Apr 20 15:08:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40063, encodeId=1b4c40063d2, content=这样子啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210115/76593437d46348539f22a2d4a7a1bbb2/8f1af15837d840569d1f9ef84030d8f5.jpg, createdBy=6a601655410, createdName=一路花开, createdTime=Wed Oct 21 11:53:00 CST 2015, time=2015-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360807, encodeId=c834136080e6e, content=<a href='/topic/show?id=14dd869559e' target=_blank style='color:#2F92EE;'>#芳香化酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86955, encryptionId=14dd869559e, topicName=芳香化酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Tue Oct 20 13:08:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362713, encodeId=cd021362e13cf, content=<a href='/topic/show?id=2ebc2535658' target=_blank style='color:#2F92EE;'>#他莫昔芬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25356, encryptionId=2ebc2535658, topicName=他莫昔芬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Tue Oct 20 13:08:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39759, encodeId=8d2b39e5908, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Mon Oct 19 19:23:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39494, encodeId=c199394940f, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:03:00 CST 2015, time=2015-10-19, status=1, ipAttribution=)]
    2016-04-20 howi
  6. [GetPortalCommentsPageByObjectIdResponse(id=1887470, encodeId=9175188e47080, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Mar 17 22:08:00 CST 2016, time=2016-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851268, encodeId=d3821851268c3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 27 02:08:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682222, encodeId=a5ec168222237, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Mon Dec 14 20:08:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895843, encodeId=1b661895843d2, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Nov 16 21:08:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828249, encodeId=ece818282495b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Apr 20 15:08:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40063, encodeId=1b4c40063d2, content=这样子啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210115/76593437d46348539f22a2d4a7a1bbb2/8f1af15837d840569d1f9ef84030d8f5.jpg, createdBy=6a601655410, createdName=一路花开, createdTime=Wed Oct 21 11:53:00 CST 2015, time=2015-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360807, encodeId=c834136080e6e, content=<a href='/topic/show?id=14dd869559e' target=_blank style='color:#2F92EE;'>#芳香化酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86955, encryptionId=14dd869559e, topicName=芳香化酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Tue Oct 20 13:08:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362713, encodeId=cd021362e13cf, content=<a href='/topic/show?id=2ebc2535658' target=_blank style='color:#2F92EE;'>#他莫昔芬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25356, encryptionId=2ebc2535658, topicName=他莫昔芬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Tue Oct 20 13:08:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39759, encodeId=8d2b39e5908, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Mon Oct 19 19:23:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39494, encodeId=c199394940f, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:03:00 CST 2015, time=2015-10-19, status=1, ipAttribution=)]
    2015-10-21 一路花开

    这样子啊!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1887470, encodeId=9175188e47080, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Mar 17 22:08:00 CST 2016, time=2016-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851268, encodeId=d3821851268c3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 27 02:08:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682222, encodeId=a5ec168222237, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Mon Dec 14 20:08:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895843, encodeId=1b661895843d2, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Nov 16 21:08:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828249, encodeId=ece818282495b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Apr 20 15:08:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40063, encodeId=1b4c40063d2, content=这样子啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210115/76593437d46348539f22a2d4a7a1bbb2/8f1af15837d840569d1f9ef84030d8f5.jpg, createdBy=6a601655410, createdName=一路花开, createdTime=Wed Oct 21 11:53:00 CST 2015, time=2015-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360807, encodeId=c834136080e6e, content=<a href='/topic/show?id=14dd869559e' target=_blank style='color:#2F92EE;'>#芳香化酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86955, encryptionId=14dd869559e, topicName=芳香化酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Tue Oct 20 13:08:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362713, encodeId=cd021362e13cf, content=<a href='/topic/show?id=2ebc2535658' target=_blank style='color:#2F92EE;'>#他莫昔芬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25356, encryptionId=2ebc2535658, topicName=他莫昔芬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Tue Oct 20 13:08:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39759, encodeId=8d2b39e5908, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Mon Oct 19 19:23:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39494, encodeId=c199394940f, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:03:00 CST 2015, time=2015-10-19, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1887470, encodeId=9175188e47080, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Mar 17 22:08:00 CST 2016, time=2016-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851268, encodeId=d3821851268c3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 27 02:08:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682222, encodeId=a5ec168222237, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Mon Dec 14 20:08:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895843, encodeId=1b661895843d2, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Nov 16 21:08:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828249, encodeId=ece818282495b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Apr 20 15:08:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40063, encodeId=1b4c40063d2, content=这样子啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210115/76593437d46348539f22a2d4a7a1bbb2/8f1af15837d840569d1f9ef84030d8f5.jpg, createdBy=6a601655410, createdName=一路花开, createdTime=Wed Oct 21 11:53:00 CST 2015, time=2015-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360807, encodeId=c834136080e6e, content=<a href='/topic/show?id=14dd869559e' target=_blank style='color:#2F92EE;'>#芳香化酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86955, encryptionId=14dd869559e, topicName=芳香化酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Tue Oct 20 13:08:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362713, encodeId=cd021362e13cf, content=<a href='/topic/show?id=2ebc2535658' target=_blank style='color:#2F92EE;'>#他莫昔芬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25356, encryptionId=2ebc2535658, topicName=他莫昔芬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Tue Oct 20 13:08:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39759, encodeId=8d2b39e5908, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Mon Oct 19 19:23:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39494, encodeId=c199394940f, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:03:00 CST 2015, time=2015-10-19, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1887470, encodeId=9175188e47080, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Mar 17 22:08:00 CST 2016, time=2016-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851268, encodeId=d3821851268c3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 27 02:08:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682222, encodeId=a5ec168222237, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Mon Dec 14 20:08:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895843, encodeId=1b661895843d2, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Nov 16 21:08:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828249, encodeId=ece818282495b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Apr 20 15:08:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40063, encodeId=1b4c40063d2, content=这样子啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210115/76593437d46348539f22a2d4a7a1bbb2/8f1af15837d840569d1f9ef84030d8f5.jpg, createdBy=6a601655410, createdName=一路花开, createdTime=Wed Oct 21 11:53:00 CST 2015, time=2015-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360807, encodeId=c834136080e6e, content=<a href='/topic/show?id=14dd869559e' target=_blank style='color:#2F92EE;'>#芳香化酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86955, encryptionId=14dd869559e, topicName=芳香化酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Tue Oct 20 13:08:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362713, encodeId=cd021362e13cf, content=<a href='/topic/show?id=2ebc2535658' target=_blank style='color:#2F92EE;'>#他莫昔芬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25356, encryptionId=2ebc2535658, topicName=他莫昔芬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Tue Oct 20 13:08:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39759, encodeId=8d2b39e5908, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Mon Oct 19 19:23:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39494, encodeId=c199394940f, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:03:00 CST 2015, time=2015-10-19, status=1, ipAttribution=)]
    2015-10-19 Guoxj3234

    赞一个

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1887470, encodeId=9175188e47080, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Mar 17 22:08:00 CST 2016, time=2016-03-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851268, encodeId=d3821851268c3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Jun 27 02:08:00 CST 2016, time=2016-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1682222, encodeId=a5ec168222237, content=<a href='/topic/show?id=d4d031e8074' target=_blank style='color:#2F92EE;'>#分泌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31780, encryptionId=d4d031e8074, topicName=分泌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0da227938338, createdName=gwc392, createdTime=Mon Dec 14 20:08:00 CST 2015, time=2015-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895843, encodeId=1b661895843d2, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Mon Nov 16 21:08:00 CST 2015, time=2015-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828249, encodeId=ece818282495b, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Apr 20 15:08:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=40063, encodeId=1b4c40063d2, content=这样子啊!, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210115/76593437d46348539f22a2d4a7a1bbb2/8f1af15837d840569d1f9ef84030d8f5.jpg, createdBy=6a601655410, createdName=一路花开, createdTime=Wed Oct 21 11:53:00 CST 2015, time=2015-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360807, encodeId=c834136080e6e, content=<a href='/topic/show?id=14dd869559e' target=_blank style='color:#2F92EE;'>#芳香化酶抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86955, encryptionId=14dd869559e, topicName=芳香化酶抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Tue Oct 20 13:08:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362713, encodeId=cd021362e13cf, content=<a href='/topic/show?id=2ebc2535658' target=_blank style='color:#2F92EE;'>#他莫昔芬#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25356, encryptionId=2ebc2535658, topicName=他莫昔芬)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa4194, createdName=cenghis, createdTime=Tue Oct 20 13:08:00 CST 2015, time=2015-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39759, encodeId=8d2b39e5908, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151005/IMG5612955936CFA7964.jpg, createdBy=18621654109, createdName=Guoxj3234, createdTime=Mon Oct 19 19:23:00 CST 2015, time=2015-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=39494, encodeId=c199394940f, content=感谢分享~, beContent=null, objectType=article, channel=null, level=null, likeNumber=140, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/05/26/5e1df344d663496bdfd43c465d409e2c.jpg, createdBy=bce679058, createdName=sunlong28, createdTime=Mon Oct 19 12:03:00 CST 2015, time=2015-10-19, status=1, ipAttribution=)]
    2015-10-19 sunlong28

    感谢分享~

    0

相关资讯

ESPE 2015:身高越高的人患癌风险越大!

在西班牙巴塞罗那举行的第54届欧洲儿科内分泌学学会会议上,研究人员发表看法:越高的人患癌风险越大。 这项研究由斯德哥尔摩大学和卡罗林斯卡医学院的研究学者组成研究团队,他们对550万名年龄超过20岁的男性和女性1958年-2011年进行了追踪随访。所有的参与者在1938年-1991年间出生,他们的成年身高范围在100-225cm。  卡罗林斯卡医学院博士生Emelie Benyi博士领导了

Genome Res:通过检测突变基因,有望诊断早期散发性乳腺癌患者

研究人员发现了乳腺细胞出现的一种基因改变,这意味着散发性乳腺癌发病率或许有增高的风险。这种基因改变可以帮助医生尽早确立早期乳腺癌的诊断,减轻患者的痛苦,并提高其生存周期。 这项发表在Genome Research的研究由来自瑞典、波兰和美国的研究人员共同参与,瑞典乌普萨拉大学免疫学、遗传学和病理学教授Jan Dumanski领导进行。 “这项研究有望探究出新的评估检测方法,以便能耐及时筛选出具有乳

BMJ:乳腺癌的早期诊断很重要--基于17万病例的研究结果

近期有研究者通过荷兰全国癌症登记信息,进行了一项以全国人口为基础的前瞻性研究,探究在拥有更好效果的辅助治疗的当今时代,乳腺癌确诊时分期情况、肿瘤生物学性质等对预后的影响。该研究纳入了1999-2012年共计n=173 797名诊断为原发性乳腺癌的女性患者,根据诊断时间将其分为2个亚组队列:1999-2005年n=80 228;2006-2012年n=93 569。研究者对两个队列进行生存率比较,且

PLoS ONE:牛身上病毒如何引发人类乳腺癌的发生?

图片来源:medicalxpress.com来自加利福尼亚大学的科学家近日通过研究首次发现感染牛白血病病毒和人类乳腺癌发病之间的神秘关联,相关研究发表于国际杂志PLoS ONE上,文章中研究者对239名女性患者的乳腺组织进行分析,对比了乳腺癌患者的样本组织和无疾病史但感染牛白血病病毒(BLV)个体的组织样本的差异,结果发现,59%的乳腺癌患者机体样本中都检测出了BLV的病毒DNA,随后通过进一步对

CEBP:不同乳腺癌亚型之间的差异性 或帮助新型疗法的开发

少数民族女性,尤其是非洲裔美国人、西班牙白人和美洲印第安人,往往容易被诊断为恶性乳腺癌,而这些患者不太可能接受推荐的方案进行治疗,因此其更容易因乳腺癌而死亡;此前研究中研究人员阐明了不同阶段疾病及患者死亡率之间的不一致性,但并没有对疾病的亚型进行分析对比。 刊登在国际杂志Cancer Epidemiology,Biomarkers & Prevention的一项研究论文中,来自西雅图Fr

ACS 2015:非遗传性早期乳腺癌应优选“单乳切除术”

2914年JAMA Surgery的一项研究发现双乳切除术的发生率从1998年的1.9%上升到了2011年的11.2%,尽管该操作比例再上升,不过众多研究均表明,双乳切除术并不会改善早期乳腺癌患者的生存,反而还会增加术后相关并发症风险。不过也有好处,那就是那些女性不用再进行每年的乳腺癌筛查或检查了。“单乳切除术”才是早期乳腺癌患者的最优选择,不仅花费少,还能改善生活质量。研究者收集了相关文献:50